Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
Objectives - Targeted therapy (TT) is an effective treatment for advanced BRAFV600-mutated melanoma, but most patients eventually acquire resistance and progress. Here, we evaluated the outcome of second-line immune checkpoint blockade (ICB) after progression on dual BRAF and MEK inhibition. - Metho...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
15 June 2019
|
| In: |
European journal of cancer
Year: 2019, Jahrgang: 116, Pages: 207-2154 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2019.05.015 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2019.05.015 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804919303181 
|
| Verfasserangaben: | Sophia Kreft, Anja Gesierich, Thomas Eigentler, Cindy Franklin, Sara Valpione, Selma Ugurel, Jochen Utikal, Sebastian Haferkamp, Christian Blank, James Larkin, Claus Garbe, Dirk Schadendorf, Paul Lorigan, Bastian Schilling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1672357454 | ||
| 003 | DE-627 | ||
| 005 | 20240323101250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190828s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2019.05.015 |2 doi | |
| 035 | |a (DE-627)1672357454 | ||
| 035 | |a (DE-599)KXP1672357454 | ||
| 035 | |a (OCoLC)1341238641 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kreft, Sophia |d 1994- |e VerfasserIn |0 (DE-588)1193611040 |0 (DE-627)1672357802 |4 aut | |
| 245 | 1 | 0 | |a Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma |c Sophia Kreft, Anja Gesierich, Thomas Eigentler, Cindy Franklin, Sara Valpione, Selma Ugurel, Jochen Utikal, Sebastian Haferkamp, Christian Blank, James Larkin, Claus Garbe, Dirk Schadendorf, Paul Lorigan, Bastian Schilling |
| 264 | 1 | |c 15 June 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.08.2019 | ||
| 520 | |a Objectives - Targeted therapy (TT) is an effective treatment for advanced BRAFV600-mutated melanoma, but most patients eventually acquire resistance and progress. Here, we evaluated the outcome of second-line immune checkpoint blockade (ICB) after progression on dual BRAF and MEK inhibition. - Methods - Patients with metastatic melanoma progressing on combined BRAF + MEK inhibition and receiving second-line ICB between 2015 and 2019 in 9 tertiary referral centres were enrolled. Demographic and clinical data and blood counts of all patients were collected retrospectively. - Results - We identified 99 patients with stage IV melanoma receiving ICB (nivolumab, pembrolizumab [n = 39] or ipilimumab plus nivolumab [n = 60]) after progression on combined TT. The median progression-free survival was similar in the PD-1 and ipilimumab plus nivolumab group (2.6 months [95% confidence interval {CI}, 2.0-3.1] vs. 2.0 [95% CI, 1.4-2.6], p = 0.15). The objective response rate was 18.0% in the PD-1 and 15.0% in the ipilimumab plus nivolumab group (p = 0.70). The disease control rate was 25.7% for monotherapy and 18.3% for combined ICB (p = 0.39). The median overall survival was 8.4 months (95% CI, 5.1-11.7) for patients receiving PD-1 monotherapy and 7.2 months (95% CI, 5.2-9.1) for patients receiving ipilimumab plus nivolumab (p = 0.86). The latter was associated with a higher rate of treatment-related adverse events (AEs). No significant association of laboratory values or clinicopathological characteristics with response to second-line ICB was observed. - Conclusions - PD-1 monotherapy and combined ipilimumab plus nivolumab show similar activity and outcome in patients with melanoma resistant to BRAF + MEK inhibition. However, combined ipilimumab plus nivolumab was associated with a higher rate of treatment-related AEs compared with monotherapy. | ||
| 650 | 4 | |a Ipilimumab | |
| 650 | 4 | |a MAPK | |
| 650 | 4 | |a Melanoma | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a Second-line treatment | |
| 700 | 1 | |a Gesierich, Anja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eigentler, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Franklin, Cindy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Valpione, Sara |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ugurel, Selma |d 1971- |e VerfasserIn |0 (DE-588)122030923 |0 (DE-627)081693532 |0 (DE-576)293057567 |4 aut | |
| 700 | 1 | |a Utikal, Jochen |d 1974- |e VerfasserIn |0 (DE-588)1026463750 |0 (DE-627)726765015 |0 (DE-576)371816580 |4 aut | |
| 700 | 1 | |a Haferkamp, Sebastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blank, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Larkin, James |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garbe, Claus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 700 | 1 | |a Lorigan, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schilling, Bastian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 116(2019), Seite 207-2154 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma |
| 773 | 1 | 8 | |g volume:116 |g year:2019 |g pages:207-2154 |g extent:9 |a Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2019.05.015 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804919303181 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190828 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 12 | ||
| 998 | |g 1026463750 |a Utikal, Jochen |m 1026463750:Utikal, Jochen |d 60000 |e 60000PU1026463750 |k 0/60000/ |p 7 | ||
| 998 | |g 122030923 |a Ugurel, Selma |m 122030923:Ugurel, Selma |d 60000 |e 60000PU122030923 |k 0/60000/ |p 6 | ||
| 999 | |a KXP-PPN1672357454 |e 3509429419 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 28.08.2019"],"recId":"1672357454","id":{"eki":["1672357454"],"doi":["10.1016/j.ejca.2019.05.015"]},"title":[{"title":"Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma","title_sort":"Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"15 June 2019","dateIssuedKey":"2019"}],"language":["eng"],"relHost":[{"pubHistory":["28.1992 -"],"titleAlt":[{"title":"EJC online"}],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Association for Cancer Research"},{"roleDisplay":"Herausgebendes Organ","display":"European School of Oncology","role":"isb"}],"recId":"266883400","id":{"zdb":["1468190-0"],"eki":["266883400"],"issn":["1879-0852"]},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"disp":"Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanomaEuropean journal of cancer","part":{"text":"116(2019), Seite 207-2154","volume":"116","extent":"9","year":"2019","pages":"207-2154"},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press"}],"language":["eng"]}],"name":{"displayForm":["Sophia Kreft, Anja Gesierich, Thomas Eigentler, Cindy Franklin, Sara Valpione, Selma Ugurel, Jochen Utikal, Sebastian Haferkamp, Christian Blank, James Larkin, Claus Garbe, Dirk Schadendorf, Paul Lorigan, Bastian Schilling"]},"person":[{"roleDisplay":"VerfasserIn","family":"Kreft","role":"aut","display":"Kreft, Sophia","given":"Sophia"},{"given":"Anja","role":"aut","display":"Gesierich, Anja","family":"Gesierich","roleDisplay":"VerfasserIn"},{"family":"Eigentler","roleDisplay":"VerfasserIn","given":"Thomas","display":"Eigentler, Thomas","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Franklin","display":"Franklin, Cindy","role":"aut","given":"Cindy"},{"given":"Sara","role":"aut","display":"Valpione, Sara","roleDisplay":"VerfasserIn","family":"Valpione"},{"roleDisplay":"VerfasserIn","family":"Ugurel","role":"aut","display":"Ugurel, Selma","given":"Selma"},{"family":"Utikal","roleDisplay":"VerfasserIn","given":"Jochen","role":"aut","display":"Utikal, Jochen"},{"family":"Haferkamp","roleDisplay":"VerfasserIn","display":"Haferkamp, Sebastian","role":"aut","given":"Sebastian"},{"display":"Blank, Christian","role":"aut","given":"Christian","family":"Blank","roleDisplay":"VerfasserIn"},{"given":"James","role":"aut","display":"Larkin, James","family":"Larkin","roleDisplay":"VerfasserIn"},{"given":"Claus","role":"aut","display":"Garbe, Claus","family":"Garbe","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Schadendorf, Dirk","given":"Dirk","family":"Schadendorf","roleDisplay":"VerfasserIn"},{"family":"Lorigan","roleDisplay":"VerfasserIn","role":"aut","display":"Lorigan, Paul","given":"Paul"},{"roleDisplay":"VerfasserIn","family":"Schilling","given":"Bastian","display":"Schilling, Bastian","role":"aut"}],"physDesc":[{"extent":"9 S."}]} | ||
| SRT | |a KREFTSOPHIEFFICACYOF1520 | ||